Adial Rebrands as Azora Therapeutics, Changes Leadership After Acquisition

Dow Jones10-29
 

Adial Pharmaceuticals is changing its name and ticker as it brings in new leadership.

The company on Wednesday said it has changed its corporate name to Azora Therapeutics, the name of a company it acquired in June. Shares will begin trading on the Nasdaq Capital Market under the symbol AZR beginning on Thursday.

Azora co-founders Matt Davidson and Julie Saiki were named the company's new chief executive officer and chief strategy officer, respectively, as part of the shifts.

The company also appointed Celia Economides as chief financial officer, David Rubenstein as chief scientist, and Ajay Duggal as consulting chief medical officer.

With the acquisition and integration in the rearview mirror, the company plans to focus on developing its lead candidate, AT177, as a treatment for ulcerative colitis. A Phase 1 clinical trial for the drug is expected to launch in the first half.

The company said that it closed private placement financing for around $32 million in gross proceeds concurrently with the June merger. The company is eligible for an additional $32 million connected to the launch of the Phase 1 trial.

 
 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment